US-based clinical-stage biotechnology company GlycoMimetics Inc plans to raise $100m by issuing shares of its common stock from time to time in a public offering.
The company plans to use funds for the production and clinical trials of its drug candidates and for general corporate purposes.
Go deeper with GlobalData
French biopharmaceutical company Erytech Pharma SA plans to raise $100m through an initial public offering of American Depositary Shares.
The company plans to use the funds for conducting Phase III clinical trials on eryaspase in the US and Europe, and other general corporate purposes.
ObsEva SA has issued seven million shares of its common stock and prepaid warrants priced at $8 a share in a private placement to raise $60m.
The French biopharmaceutical company plans to use the funds towards the research and development of its drug candidates.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUS-based biopharmaceutical company Allena Pharmaceuticals Inc plans to issue shares of its common stock in an initial public offering (IPO) to raise $92m.
The company intends to use funds from the offering to carry out Phase trials of ALLN-177 and other general corporate purposes.
Spero Therapeutics Inc plans to raise $86.25m in an initial public offering (IPO) of shares of its common stock.
The US-based biopharmaceutical company plans to use the funds for the clinical trials of SPR994 and SPR994 and for working capital purposes.
